Autolus Therapeutics Plc annual report, Q4 FY2018

Business context and reporting period

Autolus Therapeutics plc is a UK-based, clinical-stage biotechnology company developing programmed T-cell cancer therapies. This Form 20-F reports the fiscal year ended September 30, 2018, not a standalone fourth quarter. Financial statements are prepared under U.S. GAAP and reported in U.S. dollars; the company’s functional currency is pounds sterling. Autolus completed its Nasdaq IPO in June 2018.

Financial performance and liquidity

Autolus had no approved products and generated no product revenue. Grant income was $1.4 million in FY2018, compared with $1.7 million in FY2017.

Operating expenses increased with clinical-program advancement, hiring, manufacturing investment, and public-company costs. FY2018 cash used in investing activities was $9.5 million, primarily for property and equipment; financing activities provided $156.9 million, including $156.5 million of net IPO proceeds. No material debt or credit lines were reported. Total liabilities were $17.7 million, including $7.1 million of operating lease obligations disclosed as future minimum payments; additional leases entered into or expected to commence after year-end are excluded from that table. Working capital was $242.1 million and total assets were $273.2 million.

Management estimated that September 30, 2018 cash would fund current and planned operations into calendar 2021, subject to assumptions that could prove incorrect. The financial statement note more conservatively states that cash was sufficient for at least 12 months from issuance. The company expects continued losses and will need additional financing to advance candidates through approval and commercialization. Profit margins are not meaningful because there are no product sales.

Material changes versus prior period

• Net loss widened by $25.0 million year over year; R&D expense rose $20.1 million and G&A expense rose $13.7 million.
• Operating cash use increased by $15.2 million, while year-end cash rose by $110.0 million, principally reflecting IPO and other equity proceeds.
• Capital expenditures increased to $9.5 million from $2.9 million. Headcount increased to 166 from 100.
• Other income included a $4.0 million foreign-exchange gain, compared with a small loss in FY2017; foreign-currency translation reduced comprehensive income by $6.1 million.

Outlook, development, risks, and unusual items

Management expected to complete proof-of-concept phases of four hematologic-cancer Phase 1/2 programs in 2019. AUTO1, AUTO2, AUTO3 and AUTO4 were in early clinical development; AUTO5 and AUTO7 were preclinical, while AUTO6 was being studied in a CRUK-sponsored trial. These are development expectations, not financial guidance, and timing and outcomes remain uncertain. The company reported preliminary, small-cohort clinical observations, including AUTO3 responses in early trials; these data are not proof of efficacy and are not directly comparable across studies.

• Key risks include clinical failure or delay, serious treatment toxicities, patient recruitment, regulatory uncertainty, manufacturing scale-up and patient-specific supply-chain complexity, competition, and the need for additional capital.
• Management reported a material weakness in internal control over financial reporting related to complex accounting review, contract changes, and insufficient finance staffing. Disclosure controls were deemed ineffective at September 30, 2018; remediation was ongoing. The auditor issued an unqualified opinion on the financial statements but did not audit internal-control effectiveness.
• Autolus relies on licensed intellectual property from UCL Business plc and owes potential development, regulatory, commercial, and sales-based milestones and royalties. The filing also identifies third-party U.S. patents that could delay a U.S. launch of AUTO1 until expiration in 2023 and late 2024, absent a license or other resolution.
• Manufacturing capacity was being expanded, including facilities in Stevenage and a planned Enfield site. The company had no commercial-scale manufacturing experience; the Enfield site was expected to begin activity in 2020.
• Foreign-exchange exposure is material: most year-end cash was held in pounds sterling, and the company did not hedge currency risk. Brexit-related regulatory and supply-chain uncertainty was also highlighted.
• No material legal proceedings or off-balance-sheet arrangements were reported. The company had never paid dividends and did not expect to do so in the foreseeable future.

Important facts for investors to verify

• Reconcile management’s runway estimate into calendar 2021 with the financial-statement note’s “at least 12 months” statement, and monitor cash burn against clinical and facility plans.
• Track updated trial enrollment, follow-up, safety, response durability, and regulatory feedback for each clinical-stage candidate; distinguish preliminary observations from confirmatory evidence.
• Assess progress in remediating the material weakness and whether subsequent filings report effective controls and timely, reliable financial reporting.
• Confirm manufacturing-site readiness, validated capacity, product-failure rates, and the cost and timing of patient-specific delivery.
• Review UCLB license obligations and AUTO1 patent exposure, including any licensing, patent challenges, or launch-timing consequences.